Join your peers and colleagues in San Francisco to gain insight and perspective on why molecular liquid biopsies have the potential to become a fulcrum in the future of precision medicine.

1. LIQUIDBIOPSYSUMMIT.COM
Keynote Speakers
Ellen M. Beasley, Ph.D.,
Senior Vice President,
Product & Services
Research & Development,
Business &
Product Development,
Genomic Health, Inc.
Steven A. Soper, Ph.D.,
Professor, Biomedical
Engineering & Chemistry;
Associate Editor, Analyst;
Director, Center for
BioModular Multiscale
Systems, University of North Carolina
MuneeshTewari, M.D.,
Ph.D., Associate Professor,
Internal Medicine and
Biomedical Engineering &
Ray and Ruth Anderson-
Laurence M. Sprague
Memorial Research Professor, University
of Michigan Health System
Symposium June 22
Circulating Markers in Cancer:
Tools for Identification, Evaluation andTranslation
Dinner Short Course June 23
Molecular Beacons; Stellaris FISH Probes; and
SuperSelective PCR Primers for Liquid Biopsies
Conference Sessions June 22 - 24
Oncology: Liquid Biopsies Are Advancing into the Clinic
Tools that Capture, Amplify and Analyze Minute
Amounts of Nucleic Acids
Moving Beyond Cancer:Tackling OtherTargets
Detecting the Role of Extracellular RNAs in
Health and Disease
LIQUIDBIOPSY
SUMMIT
THE
JUNE 22 - 24, 2016
HOTEL KABUKI | SAN FRANCISCO, CALIFORNIA
Refining Circulating Cell-Free Tools and Technologies for Translational Research
final agenda
Register by March 18
Saveupto$
400
CORPORATE
SUPPORT
SPONSOR
CORPORATE
SPONSOR
Join your peers and colleagues in San Francisco
to gain insight and perspective on why molecular
liquid biopsies have the potential to become a
fulcrum in the future of precision medicine.
This is an unprecedented time in biomolecular
medicine. Recent scientific findings have determined
biofluids consist of circulating cell-free (cf)DNA and
extracellular (ex)RNA from multiple tissues within
the body. In addition, the rapid development of highly
sensitive and accurate next-generation sequencing
(NGS) technologies has empowered researchers
to analyze the role of these biomolecules in health,
disease and treatment response. However, there
remains considerable insecurity associated with
biofluid-based DNA/RNA analytical methods which
must be solved before liquid biopsies can be
implemented for broader routine applications.

2. 2 LIQUIDBIOPSYSUMMIT.COM
Present Your Research
Poster and Save $50!
Cambridge Healthtech Institute
encourages attendees to gain further
exposure by presenting their work
in the poster sessions. To secure
a poster board and inclusion in the
conference materials, your abstract
must be submitted, approved and your
registration paid in full by May 13, 2016
Reasons you should present your
research poster at this conference:
• Your poster will be seen by
our international delegation,
representing leaders from top
pharmaceutical, biotech, academic
and government institutions
• Receive $50 off your registration
• Your poster abstract will be published
in our conference materials
molecularbeacons;stellarisfish
probes;andsuperselectivepcr
primersforliquidbiopsies
dinnershortcourse*
THURSDAY, JUNE 23 | 5:45-8:45 PM
SC1: Molecular Beacons;Stellaris FISH Probes; and
SuperSelective PCR Primers for Liquid Biopsies
Instructors:
Fred Russell Kramer, Ph.D., Professor, Microbiology, Biochemistry and
Molecular Genetics, New Jersey Medical School, Rutgers University
Sanjay Tyagi, Ph.D., Professor, Medicine, Public Health Research Institute,
New Jersey Medical School, Rutgers University
Section 1: Finicky and Sloppy Molecular Beacons
Section 2: Imaging Single mRNA Molecules in Living and Fixed Cells
Section 3: Multiplex Real-Time PCR Assays that Assess the
Abundance of Extremely Rare Mutations Associated with Cancer
Please visit the conference website for a complete syllabus.
* Separate registration required
CORPORATE SUPPORT SPONSORCORPORATE SPONSOR
EVENT FEATURES
The Liquid Biopsy Summit is uniquely designed to provide
up-to-date coverage for this rapidly evolving field through:
Networking
• Breakout Discussion Groups
• Reception and Refreshment Breaks
One-on-One Discussions
• Poster Sessions
• Q&A following Presentations
• Solution Providers
In-Depth Coverage
• Symposium on current technologies for CTCs
and (cf)DNA
• Short Course on PCR: Probes, Primers, and Beacons
• Panel Discussion on current challenges and future
opportunities
• Identifying biofluid molecular markers (cf)DNA and
(ex)RNA from tissue
• Latest research from academic, biotech, and
established diagnostic companies
• Providing faster, cheaper, and less invasive biopsies
• Developing clinically actionable tests
• Expanding molecular targets and indications
• Combining liquid biopsies with personalized therapies
Unique Japantown Location
• Convenient location near many
San Francisco attractions
• Rich in Culture and Luxury
#LBS16STAY CONNECTED

3. LIQUIDBIOPSYSUMMIT.COM 3
WEDNESDAY, JUNE 22
7:30 am Symposium Registration and Morning Coffee
From CTCs to New Diagnostics
8:30 Organizer’s Opening Remarks
Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute
8:35 Chairperson’s Opening Remarks
Lidia C. Sambucetti, Ph.D., Senior Director, Cancer Research Technologies,
SRI International Biosciences Division
»»8:45 KEYNOTE PRESENTATION: NewTools for
the Isolation of Circulating Markers: Microfluidic
Systems for the Analysis of Circulating Cells,
Cell-Free DNA and Exosomes
Steven A. Soper, Ph.D., Professor, Biomedical Engineering & Chemistry;
Associate Editor, Analyst; Director, Center for BioModular Multiscale
Systems, University of North Carolina
Liquid biopsies are generating interest within the biomedical community
due to the simplicity for securing important markers to realize precision
medicine. These circulating markers consist of whole cells such as CTCs,
molecules such as cell-free DNA and nanovesicles such as exosomes.
We are developing microfluidic systems that can process whole blood
directly and select all three of these markers from a single blood sample.
The devices can not only collect the markers from blood samples, but
also perform molecular analysis on their cargo.
9:15 OpticalTechnologies for CTC Analysis
Gregory Faris, Ph.D., Program Manager, Optical Systems, Discovery
Technologies, SRI International
This talk describes two technologies for CTC analysis. The first is a non-
enrichment method for selection of CTCs using optical imaging. The second
method uses laser heating for multiplexed in situ PCR and RT-PCR in nanoliter
droplets without removing cells.
9:45Trends in Automating CTC Capture: Progress towards a
Simple and Inexpensive Assay
Siddarth Rawal, M.D., COO, Circulogix Inc.; Clinical Research Associate, Miller
School of Medicine, University of Miami
Circulating tumor cells (CTC) have been regarded as important biomarkers for
cancer prognosis, monitoring treatment response and companion diagnostics to
assess efficacy of novel targeted drugs in development. However, the effective and
complete enrichment of these rare events from whole blood remains a non-trivial,
manual-intensive and expensive endeavor. Reliable automated technologies are
needed to provide a consistent and easy workflow to generate exciting discoveries.
10:15 Networking Coffee Break
10:45 CirculatingTumor Cells in the Peripheral Blood Decrease in
Numbers withTreatment in Patients with Various Carcinomas
Rebecca (Becky) Suttmann, MS, Senior Scientific Researcher, Oncology
Biomarker Development, Genentech, Inc.
We summarize findings of CTC enumeration utilizing the CellSearch® platform
for isolating and enumerating cells from nearly 10,000 fresh whole-blood samples
from cancer patients enrolled in 20 clinical trials conducted by Genentech over
four years. Incidence and changes in CTC number and presence of targeted
markers were measured. Evaluation of numerous patient samples across multiple
indications has provided an opportunity to assess utility of CTC analysis on the
CellSearch® platform in the context of clinical drug development.
11:15 Microfluidics-Based Biomarker Isolation and Analysis for
Cancer Detection from Blood Samples
Rolf Muller, Ph.D., CEO, BioFluidica, Inc.
BioFluidica has developed a comprehensive platform technology to isolate
and detect rare biomarkers in blood samples. The technology allows large-
volume, whole-blood processing with high biomarker recovery and purity.
The technology is based on microfluidic isolation technology and has been
clinically validated for six different cancer types. We focus on the detection of
minimal residual disease in acute myeloid leukemia patients using circulating
leukemic cells selected from blood.
11:45 Sponsored Presentation (Opportunity Available)
12:15 pm Session Break
12:30 Luncheon Presentation (Sponsorship Opportunity Available)
or Lunch onYour Own
1:00 Session Break
Big Data and Applications of Analysis of ctDNA
2:00 Chairperson’s Remarks
Lidia C. Sambucetti, Ph.D., Senior Director, Cancer Research Technologies, SRI
International Biosciences Division
2:05 Studying theTumor Microenvironment with Big Data
Dvir Aran, Ph.D., Research Scientist, Atul Butte Laboratory, Institute for
Computational Health Sciences, University of California, San Francisco
Public genomic data now offer the opportunity for bioinformaticians to study
the tumor microenvironment. I present a systematic pan-cancer analysis of
tumor purity, which demonstrates how “purity” significantly biases genomic
analyses. However, this also allows new opportunities to study the crosstalk
of the microenvironment with the cancer. I conclude with our recent advances
to dissect the microenvironment further.
2:35 Monitoring CirculatingTumor DNA to Assess
Chemotherapeutic Effectiveness
Timothy Butler, Research Scientist, Paul Spellman Laboratory, Knight Cancer
Institute, Oregon Health & Science University
Circulating-tumor DNA (ctDNA) analysis has the potential to improve how we
monitor and treat patients with cancer. In this study we utilize a hybrid-capture
approach to sensitively monitor the ctDNA of breast cancer patients before,
during, and after undergoing neoadjuvant chemotherapy. Our findings offer
interesting insights into patient responses to neoadjuvant chemotherapy, and
may improve prognostic and treatment decisions following therapy.
3:05 Sponsored Presentation (Opportunity Available)
3:20 Networking Refreshment Break
3:45 Liquid Biopsy in Prostate Cancer
John S. Witte, Ph.D., Professor and Head, Division of Genetic and Cancer
Epidemiology; Associate Director, Institute for Human Genetics; Co-Leader,
Cancer Center Program in Cancer Genetics, University of California, San Francisco
4:15 Liquid Biopsies – Pushing the Envelope
Pamela Paris, Ph.D., Professor of Urology, Department of Urology, University
of California, San Francisco
4:45 PANEL DISCUSSION: Current and Future Applications of
Liquid Biopsies in Cancer
All agree CTCs and ctDNA are prognostic and predictive biomarkers
for cancer. However, different approaches for CTCs/ctDNA detection
and analysis to identify these tumor cell subpopulations need technical
standardization before their clinical validity and biological specificity may
be adequately investigated. Join these panelists as they discuss the
current challenges and future opportunities for liquid biopsies.
Panelists:
Ellen M. Beasley, Ph.D., Genomic Health, Inc.
Geoff Otto, Ph.D., Foundation Medicine
Steven A. Soper, Ph.D., University of North Carolina
Rebecca (Becky) Suttmann, MS, Genentech, Inc.
John S. Witte, Ph.D., University of California, San Francisco
5:30 Welcome Reception in the Exhibit Hall
with Poster Viewing
6:30 Close of Day
circulatingMarkersincancer:Tools for Identification, Evaluation and Translation
symposium

4. 4 LIQUIDBIOPSYSUMMIT.COM
WEDNESDAY, JUNE 22
3:45 pm Main Conference Registration
4:45 PANEL DISCUSSION: Current and Future Applications
of Liquid Biopsies in Cancer
All agree CTCs and ctDNA are prognostic and predictive biomarkers
for cancer. However, different approaches for CTCs/ctDNA detection
and analysis to identify these tumor cell subpopulations need technical
standardization before their clinical validity and biological specificity may
be adequately investigated. Join these panelists as they discuss the
current challenges and future opportunities for liquid biopsies.
Panelists:
Ellen M. Beasley, Ph.D., Genomic Health, Inc.
Geoff Otto, Ph.D., Foundation Medicine
Steven A. Soper, Ph.D., University of North Carolina
Rebecca (Becky) Suttmann, MS, Genentech, Inc.
John S. Witte, Ph.D., University of California, San Francisco
5:30 Welcome Reception in the Exhibit Hall
with Poster Viewing
6:30 Close of Day
THURSDAY, JUNE 23
8:00 am Morning Coffee
Oncology: Liquid Biopsies Are Advancing into the Clinic
8:30 Organizer’s Opening Remarks
Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute
8:35 Chairperson’s Opening Remarks
Jamie Platt, Ph.D., MB(ASCP), Molecular Pathology Laboratory Network
»»8:45 KEYNOTE PRESENTATION: Liquid Biopsies in
Cancer Disease Management
Ellen M. Beasley, Ph.D., Senior Vice President, Product & Services Research
& Development, Business & Product Development, Genomic Health, Inc.
Liquid biopsies can be used to monitor tumor dynamics including
recurrence, or to profile individual genetic and genomic markers that
are informative of treatment options.Together, these complementary
approaches provide precision solutions to help manage disease along the
patient cancer journey.These also call for different development, analytical
and clinical validation strategies, as well as demonstration of clinical utility.
9:30 Circulating RNAs as Noninvasive Biomarkers in Colorectal
Cancer
Ajay Goel, Ph.D., Investigator/Professor & Director, Center for Gastrointestinal
Research; Director, Center for Epigenetics, Cancer Prevention and Cancer
Genomics, Baylor Research Institute and Charles A. Sammons Cancer Center,
Baylor University Medical Center
Given their cancer-specific pattern of expression, remarkable stability and
presence in blood and other body fluids, noncoding RNAs (ncRNAs) are
considered to be highly promising “liquid biopsy” cancer biomarkers.
Accumulating evidence firmly supports the existence of unique “ncRNA
signatures” that can not only facilitate earlier detection of the tumor, but
can also assist in predicting disease recurrence and therapeutic outcome to
current treatment regimens.
10:00 Accessing Genetic Information with Liquid Biopsies
Jian-Bing Fan, Ph.D., CEO, AnchorDx Corp.
The molecular liquid biopsies approach provides non-invasive access to
genetic information – somatic mutations, epigenetic changes, and differential
expression – about the physiological conditions of our body and diseases.
With the rapid development of highly sensitive and accurate technologies
such as next-generation sequencing, it is now possible to reliably analyze
CTCs and circulating nucleic acids in a clinic setting, which opens a valuable
avenue for future genetic studies and human disease diagnosis.
10:30 Coffee Break in the Exhibit Hall with Poster Viewing
11:00 Analytic Validation of an NGS-Based Clinical ctDNA Assay
Geoff Otto, Ph.D., Senior Director, Molecular Biology & Sequencing,
Foundation Medicine
Profiling circulating tumor DNA (ctDNA) for the genomic alterations (GA)
driving oncogenesis promises to provide insight into cancer biology, inform
therapy selection when conventional biopsies are unobtainable and enable
monitoring of response to therapy. A clinical, NGS-based ctDNA assay was
developed, highly accurate detection of GA was analytically validated and
clinical utility investigated from patient-matched FFPE and blood samples
across lung, breast and colon cancer at different disease stages.
11:30 Nucleosome Footprints in Cell-Free DNA Are Evidence of
ItsTissues of Origin
Andrew Hill, Graduate Research Fellow, Jay Shendure Laboratory, Genome
Sciences, University of Washington
Nucleosome positioning varies across cell types. Some proportion of cell-
free DNA (cfDNA) is protected by nucleosomes, which in principle could
allow detection of cell types contributing to cfDNA. We infer nucleosome
positioning in cfDNA to identify abnormal contributions in pathologies such as
cancer. Because this method does not rely on genetic differences between
healthy and pathological contributions, it could potentially broaden the scope
of cfDNA-based monitoring and diagnostics.
12:00 pm Presentation to be Announced Sponsored by
12:15 Sponsored Presentation
(Opportunity Available)
12:30 Session Break
12:45 Luncheon Presentation (Sponsorship Opportunity Available)
or Lunch onYour Own
1:15 Session Break
Tools that Capture, Amplify and Analyze Minute
Amounts of Nucleic Acids
2:00 Chairperson’s Remarks
Ellen M. Beasley, Ph.D., Genomic Health, Inc.
2:05 Nanocarbon-Coated Porous Anodic Alumina for Biological
Applications
Steven Prawer, Ph.D., D.Sc., Professor of Physics, School of Physics,
University of Melbourne
Here we demonstrate a new broad-range sensor platform for ultrasensitive
and selective detection of circulating DNA down to the single-molecule level.
The biosensor is based on a chemically functionalized nanoporous diamond-like
carbon (DLC)-coated alumina membrane.The few nanometer-thick, yet perfect
and continuous DLC coating confers the chemical stability and biocompatibility
of the sensor, allowing its direct application in biological conditions.
liquidbiopsysummitTHE
Conference Agenda

5. LIQUIDBIOPSYSUMMIT.COM 5
2:35T Oligo-Primed Polymerase Chain Reaction (TOP-PCR): A
Robust Method for the Amplification of Minute Amount of DNA
Fragments from Body Fluids
Kuo Ping Chiu, Ph.D., Associate Research Fellow, Genomics Research Center,
Academia Sinica
We have developedT oligo-primed PCR (TOP-PCR) for comprehensive
amplification of minute DNA fragments.TOP-PCR adopts homogeneous adaptor
(generated by P oligo andT oligo) for efficient ligation to A-tailed DNA, followed by
PCR amplification primed byT oligo. We demonstrate thatTOP-PCR maintains the
size profile of the DNA sample and is a superior method for recovering minute
DNA in body fluids. It maximizes the resolution of Illumina sequencing.
3:05 Sponsored Presentation (Opportunity Available)
3:20 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Sample Prep in Genetic Assay Development
Toumy Guettouche, Ph.D., Director, Early Development & Genetics Assay
Development, Sequencing Unit, Roche Molecular Systems
4:30 Sample Prep in Liquid Biopsy; CanWe AlwaysWin the Lottery?
Jamie Platt, Ph.D., MB(ASCP), Vice President, Genomic Solutions, Molecular
Pathology Laboratory Network
The introduction of NGS has enabled some remarkable applications which allow for
less invasive specimen acquisition, and improved sensitivity and specificity. Liquid
biopsy is one application that holds enormous promise as a tool for monitoring
therapeutic response, detect residual disease, and even provide an earlier
diagnosis. However, one fact remains: you can’t detect what you haven’t sampled.
The key issues and opportunities for liquid biopsy sample prep will be discussed.
5:00 Next-Generation Liquid Biopsy:Tumor Monitoring from
Droplet Volumes of Blood
Chen-Hsiung Yeh, Ph.D., CSO, Circulogene Theranostics
Circulating cell-free DNA (cfDNA) can provide a global longitudinal picture of
tumor heterogeneity. Large sample volume, low yield, and labor intensiveness
are major obstacles for clinical application of cfDNA-based testing. Our
proprietary cfDNA sample preparation breakthrough enables clinicians to work
with a sample volume as small as 20 microliters (via a finger prick), which can
further expedite clinical decision-making and identify targeted therapies for
eligible patients in a time- and cost-efficient manner.
5:30 Close of Day and Short Course Registration
5:45-8:45 Dinner Short Course*
SC1: Molecular Beacons; Stellaris FISH Probes; and
SuperSelective PCR Primers for Liquid Biopsies
*Separate registration required. See page 2 for details.
FRIDAY, JUNE 24
7:30 am BREAKFAST BREAKOUT DISCUSSION GROUPS
Chew over breakfast and provocative discussion topics with your peers.These
are moderated discussions with brainstorming and interactive problem solving,
allowing conference participants from diverse backgrounds to exchange ideas
and experiences and develop future collaborations around a focused topic.
Standards of Evidence, Methods and Materials to Accelerate
Liquid Biopsy Development and Adoption
Moderator: Ellen M. Beasley, Ph.D., Genomic Health, Inc.
Taking ctDNA to the Clinic: Best Applications of Liquid Biopsies
to Improve CancerTreatment
Moderator: Timothy Butler, Oregon Health & Science University
Use of Systems or Computational Biology to Decipher the
Molecular Information that Arises from High-Throughput Liquid
Biopsies from the Plasma
Moderator: Stephen Y. Chan, M.D., Ph.D., University of Pittsburgh Medical
Center
NGS for Clinical Infectious Disease Diagnostics
Moderator: Charles Chiu, M.D., Ph.D., University of California, San Francisco
Nanoscience in the Service of BiologicalTechnologies
Moderator: Steven Prawer, Ph.D., D.Sc., University of Melbourne
Additional Breakout Discussion Groups to be Announced
Moving Beyond Cancer:Tackling OtherTargets
8:45 Chairperson’s Opening Remarks
Charles Chiu, M.D., Ph.D., University of California, San Francisco
8:50 Cell-Free DNA inTransplant Medicine
Kiran K. Khush, M.D., MAS, FACC, Associate Professor, Medicine, Division of
Cardiovascular Medicine, Stanford University School of Medicine
This talk reviews clinical applications of cell-free DNA testing in the field
of solid organ transplantation. Topics covered include (1) monitoring for
acute rejection, with illustrative cases from heart and lung transplantation,
(2) monitoring of the transplant recipients’ virome, and how it changes
with introduction and weaning of immunosuppression, and (3) non-biased
detection of disease-causing pathogens in transplant recipients.
9:20 Liquid Biopsy of the HIV Latent Reservoir in Patients on
Anti-RetroviralTherapies
Xiaohe Liu, Ph.D., Senior Scientist & Co-Leader, Rare Cell Technology
Program, Biosciences Division, SRI International
A major hurdle in HIV eradication research is the lack of robust assays to
characterize the reservoir cells that harbor HIV in the presence of anti-retroviral
therapy (ART). We applied FAST (Fiber-optic Array ScanningTechnology) to
detect and characterize rare cells that express HIV proteins in peripheral blood
of patients on ART. Our data suggest that FAST may be a new, important
method to identify and measure replication competent proviruses.
9:50 Metagenomic Next-Generation Sequencing for Diagnosis of
Infectious Diseases from Cell-Free Fluids
Charles Chiu, M.D., Ph.D., Associate Professor, Laboratory Medicine and
Medicine/Infectious Diseases; Director, UCSF-Abbott Viral Diagnostics and
Discovery Center; Associate Director, UCSF Clinical Microbiology Laboratory,
UCSF School of Medicine, University of California, San Francisco
Metagenomic next-generation sequencing (mNGS) is a powerful approach to
the diagnosis of infectious diseases, as it does not rely on targeted primers
or probes. A single sequencing test is able to identify all viruses, bacteria,
fungi, and parasites in clinical samples. Here we describe implementation
of a clinically validated mNGS assay from cerebrospinal fluid to diagnose
meningitis and encephalitis in critically ill hospitalized patients.
10:20 Sponsored Presentation (Opportunity Available)
10:35 Coffee Break in the Exhibit Hall with Poster Viewing
11:10 Looking for the Free Agents in Blood: High-Sensitivity RNA-
Seq Approaches for Detecting Infectious Agents in Liquid Biopsies
Andrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor,
Genetics, Rutgers University
11:40 Using Immune Profiles to Categorize Neurological Disease
Nancy Monson, Ph.D., Associate Professor, Department of Neurology
and Neurotherapeutics & Department of Immunology, University of Texas
Southwestern Medical Center
Cerebrospinal fluid (CSF) samples have been a useful tool in the diagnosis
of neurological diseases involving the central nervous system (CNS). Our
laboratory has focused on finding new ways to use CSF as a diagnostic tool
for multiple sclerosis, an autoimmune disease of the CNS. We discovered that
antibody genetics of CSF-derived B cells can be used to identify patients who
have MS and patients who will develop MS in the future with 84-92% accuracy.
12:10 pm Sponsored Presentation (Opportunity Available)
12:40 Session Break
12:45 Luncheon Presentation (Sponsorship Opportunity Available)
or Lunch onYour Own
1:15 Session Break

6. 6 LIQUIDBIOPSYSUMMIT.COM
RECENT REPORT AVAILABLE FROM INSIGHT PHARMA REPORTS
Detecting the Role of Extracellular RNAs in Health
and Disease
2:00 Chairperson’s Remarks
Lynne T. Bemis, Ph.D., University of Minnesota
»»2:05 KEYNOTE PRESENTATION: Circulating
Extracellular RNAs as Biomarkers
Muneesh Tewari, M.D., Ph.D., Associate Professor, Internal Medicine and
Biomedical Engineering & Ray and Ruth Anderson-Laurence M. Sprague
Memorial Research Professor, University of Michigan Health System
MicroRNAs as well as other classes of RNA have been found to be
present in blood and other biofluids in extracellular form and are being
actively investigated as biomarkers for cancer and many other diseases.
I review some of the history of this field, current knowledge about
circulating microRNA biochemistry, key considerations and pitfalls to
avoid in performing extracellular RNA biomarker studies, as well as the
outlook for the future.
2:45The Biology of Circulating MicroRNAs in Cardiovascular
Health and Disease
Stephen Y. Chan, M.D., Ph.D., Director, Center for Pulmonary Vascular Biology
and Medicine; Associate Professor of Medicine, Department of Medicine,
University of Pittsburgh Medical Center
Plasma-based circulating microRNAs have attracted attention in cardiovascular
medicine, relevant for the study of disease states and normal physiology. I
describe our recent findings regarding the dynamic regulation and biological
actions of circulating microRNAs in aerobic exercise and in pulmonary
hypertension. I discuss new technologies to detect and quantify these factors.
Finally, I discuss the potential utility of circulating microRNAs as putative
cardiovascular biomarkers and/or therapeutic targets.
3:15 Sponsored Presentation (Opportunity Available)
3:30 Refreshment Break in the Exhibit Hall with Poster Viewing
4:00 Comparison of Extracellular RNA Profiles across Biofluids
andTheir Utility for Biomarker Development
Kendall Van Keuren-Jensen, Ph.D., Associate Professor, Neurogenomics, TGen
Examination of RNA species from several biofluids can provide a range of
information about an individual. For example, there are varying amounts of
tissue-specific data and exogenous RNA species present among different
biofluids. Depending on the type of disease or location of injury, the choice of
biofluid may be an important consideration for biomarker development.
4:30 tRNA Fragments Join the Repertoire of Small RNAs with
Potential as Biomarkers
Lynne T. Bemis, Ph.D., Chair, Biomedical Sciences, University of Minnesota
tRNA fragments are often abundant in high-throughput studies of extracellular
RNA. Initially regarded as breakdown products of mature tRNA, and thus of
little consequence, they are now being studied for their regulatory function
in health and disease. A review of our current understanding of the functions
attributed to these fragments will be presented.
5:00 Close of Conference
Liquid Biopsy:An Emerging Market for Radically Improved Cancer Management
Cancer diagnostics based on measuring
biomarkers in tissue samples has already
in the past decade provided revolutionary
advances in diagnosis, prognosis, and
therapy selection. A major drawback of
the tissue-based approach centers on
the need for invasive surgical procedures
in sample collection, which in a great
many instances preclude following the
progression or regression of disease
during therapy.
In recent years, an impressive number
of cancer biomarker researchers have
turned their attention to the analysis of markers present in
biological fluids, which can be collected with minimal invasiveness
and permit following the disease over time. This highly dynamic
field has come to be called liquid biopsy. In the past few years
a significant and growing number of startups and several major
companies have taken up the challenge of commercializing and
offering liquid biopsy products and services to the market.
These procedures, for the most part,
query blood samples for information to
be gleaned from circulating tumor cells
(CTCs), circulating tumor DNA (ctDNA)
fragments, and extracellular vesicles (EVs).
CTCs have the longest history as subjects
for liquid biopsy. Indeed, one decade-old
commercial product has already garnered
FDA approval for in vitro diagnostic use.
Circulating tumor DNA, a more recent
entry on the liquid biopsy scene, is fast
becoming an alternative or adjunct to
CTC assays. EVs are the newest and least
developed of the three liquid biopsy sample sources, and while
highly promising, their ultimate value has yet to be fully established.
This report explores the background, history and basic research of
liquid biopsy covering the three sample categories that dominate
liquid biopsy today: circulating tumor cells (CTCs), circulating
tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as
exosomes). This report also details the commercial aspects, market
dynamics, and trends of liquid biopsy.
InsightPharmaReports.com
A Division of Cambridge Healthtech Institute
Liquid Biopsy:
An Emerging Market for Radically
Improved Cancer Management
Kenneth Rubenstein, Ph.D.
ExpertIntelligenceforBetterDecisions

7. LIQUIDBIOPSYSUMMIT.COM 7
SPONSORSHIP, EXHIBIT, AND
LEAD GENERATION OPPORTUNITIES
CHI offers comprehensive sponsorship packages which include presentation
opportunities, exhibit space, branding and networking with specific prospects.
Sponsorship allows you to achieve your objectives before, during, and long
after the event. Any sponsorship can be customized to meet your company’s
needs and budget. Signing on early will allow you to maximize exposure to
qualified decision-makers.
Podium Presentations – Available within the Main Agenda!
Showcase your solutions to a guaranteed, targeted audience. Package includes a
15- or 30-minute podium presentation within the scientific agenda, exhibit space,
on-site branding, access to cooperative marketing efforts by CHI, and more.
Breakfast & Luncheon Podium Presentations
Opportunity includes a 30-minute podium presentation. Boxed lunches are
delivered into the main session room, which guarantees audience attendance
and participation. A limited number of presentations are available for
sponsorship and they will sell out quickly. Sign on early to secure your talk!
Invitation-Only VIP Dinner/Hospitality Suite
Sponsors will select their top prospects from the conference pre-registration
list for an evening of networking at the hotel or at a choice local venue. CHI will
extend invitations and deliver prospects, helping you to make the most out of
this invaluable opportunity. Evening will be customized according to sponsor’s
objectives i.e.:
• Purely social • Focus group
• Reception style • Plated dinner with specific conversation focus
Exhibit
Exhibitors will enjoy facilitated networking opportunities with qualified
delegates. Speak face-to-face with prospective clients and showcase your latest
product, service, or solution.
One-on-One Meetings
Select your top prospects from the pre-conference registration list. CHI will
reach out to your prospects and arrange the meeting for you. A minimum
number of meetings will be guaranteed, depending on your marketing
objectives and needs. A very limited number of these packages will be sold.
Additional branding and promotional opportunities are available, including:
• Conference Tote Bags
• Literature Distribution (Tote Bag
Insert or Chair Drop)
• Badge Lanyards
• Padfolios
• Program Guide Advertisement
Looking for additional ways to drive leads to your sales team?
CHI’s Lead Generation Programs will help you obtain more targeted, quality
leads throughout the year. We will mine our database of 800,000+ life science
professionals to your specific needs. We guarantee a minimum of 100 leads
jper program! Opportunities include:
• Whitepapers • Web Symposia
• Custom Market Research Surveys • Podcasts
For sponsorship and exhibit information, please contact:
Terry Manning, Business Development Manager
781-972-1349 | tmanning@healthtech.com
OFFICIAL PUBLICATION LEAD SPONSORING PUBLICATIONS SPONSORING PUBLICATIONS
WEB PARTNERS
HOTEL & TRAVEL INFORMATION
Conference Venue and Hotel:
Hotel Kabuki
1625 Post Street
San Francisco, CA 94115
Phone: 415-922-3200
Reservations: Go to the travel page of LiquidBiopsySummit.com
Discounted Room Rate: $209 s/d
Discounted Room Rate Cut-off Date: May 26, 2016
Reservations and AdditionalTravel Information:
Go to the travel page of LiquidBiopsySummit.com

8. Please refer to the Registration Code below:
How to Register: LiquidBiopsySummit.com
reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288
Please use keycode
CFDX F
when registering!
Pricing and Registration Information
SHORT COURSE PRICING
Academic, Government,
Commercial Hospital-affiliated
Short Course Only $699 $399
Thursday, June 23 SC1: Molecular Beacons; Stellaris FISH Probes; and SuperSelective PCR Primers for Liquid Biopsies
SYMPOSIUM PRICING
Symposium Only $999 $599
Wednesday, June 22 S1: Circulating Markers in Cancer: Tools for Identification, Evaluation and Translation
CONFERENCE PRICING
STANDARD PACKAGE (Includes Symposium & Conference Program. Excludes Short Course.)
Early Registration Discount until March 18, 2016 $2199 $1129
Advance Registration Discount until May 13, 2016 $2349 $1179
Registrations after May 13, 2016, and on-site $2549 $1249
BASIC PACKAGE (Includes Conference Program Only. Excludes Symposium and Short Course.)
Early Registration Discount until March 18, 2016 $1549 $729
Advance Registration Discount until May 13, 2016 $1749 $799
Registrations after May 13, 2016, and on-site $1949 $879
INSIGHT PHARMA REPORT PRICING
INSIGHT PHARMA REPORT: LIQUID BIOPSY (Order Insight Pharma Report at Special Discounted Rate)
Liquid Biopsy Report $1100 $700
CONFERENCE DISCOUNTS
Poster Submission - Discount ($50 Off): Poster abstracts are due by May
13, 2016. Once your registration has been fully processed, we will send an
email containing a unique link allowing you to submit your poster abstract.
If you do not receive your link within 5 business days, please contact
jring@healthtech.com. *CHI reserves the right to publish your poster title
and abstract in various marketing materials and products.
REGISTER 3 ­- 4th IS FREE: Individuals must register for the same confer-
ence or conference combination and submit completed registration form
together for discount to apply.
Group Discounts: Discounts are available for multiple attendees from the
same organization. For more information on group rates contact
David Cunningham at +1-781-972-5472
Alumni Discount - SAVE 20%: CHI appreciates your participation at our events.
As a result of the great loyalty you have shown us, we are pleased to extend to
you the exclusive opportunity to save an additional 20% off the registration rate.
ADDITIONAL REGISTRATION DETAILS
Each registration includes all conference
sessions, posters and exhibits, food functions,
and access to the conference proceedings link.
Handicapped Equal Access: In accordance with
the ADA, Cambridge Healthtech Institute is
pleased to arrange special accommodations
for attendees with special needs. All requests
for such assistance must be submitted in
writing to CHI at least 30 days prior to the start
of the meeting.
To view our Substitutions/Cancellations
Policy, go to healthtech.com/regdetails
Video and or audio recording of any kind is
prohibited onsite at all CHI events.
Reports designed to keep life science professionals
informed of the salient trends in pharma technology,
business, clinical development, and therapeutic
disease markets
InsightPharmaReports.com
Contact Adriana Randall,
arandall@healthtech.com, +1-781-972-5402.
Barnett is a recognized leader in clinical
education, training, and reference guides for
life science professionals involved in the drug
development process. For more information,
visit BarnettInternational.com.
Complimentary news delivered to your inbox
Insights on the innovation between clinical
trial management and delivery of care.
ClinicalInformaticsNews.com
News on the data deluge in petascale
computing and the tools to deliver
individualized medicine.
Bio-ITWorld.com
Emerging Technologies in Diagnostics
DiagnosticsWorldNews.com
Cambridge Healthtech Institute
250 First Avenue, Suite 300
Needham, MA 02494
www.healthtech.com
Fax: 781-972-5425
LIQUIDBIOPSYSUMMITTHE
JUNE 22 - 24, 2016 HOTEL KABUKI | SAN FRANCISCO, CALIFORNIA
If you are unable to attend but would like to purchase The Liquid Biopsy
Summit 2016 CD for $350 (plus shipping), please visit LiquidBiopsySummit.
com. Massachusetts delivery will include sales tax.